Table 3 Association of Lp(a) with MACE.

From: The nonlinear association between lipoprotein(a) and major adverse cardiovascular events in acute coronary syndrome patients with three-vessel disease

 

Model 1

 

Model 2

 

Model 3

 

Model 4

 

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

T1

Ref.

-

Ref.

-

Ref.

-

Ref.

-

T2

1.223 (0.973, 1.539)

0.085

1.150 (0.913, 1.447)

0.235

1.149 (0.911, 1.448)

0.240

1.051 (0.833, 1.325)

0.677

T3

1.850 (1.493, 2.293)

< 0.001

1.708 (1.376, 2.120)

< 0.001

1.657 (1.334, 2.059)

< 0.001

1.363 (1.088, 1.709)

0.007

P for trend

-

< 0.001

-

< 0.001

-

< 0.001

-

0.008

Lp(a)

1.001 (1.001, 1.001)

< 0.001

1.001 (1.001, 1.001)

< 0.001

1.001 (1.001, 1.001)

< 0.001

1.001 (1.000, 1.001)

< 0.001

Log10Lp(a)

1.985 (1.567, 2.516)

< 0.001

1.821 (1.434, 2.313)

< 0.001

1.762 (1.388, 2.237)

< 0.001

1.437 (1.122, 1.841)

0.004

  1. Model 1: unadjusted; Model 2: adjusted for age; Model 3: adjusted for age, hypertension, diabetes, stroke, CKD, antihypertensive drugs, and antidiabetic drugs; Model 4: adjusted for Model 3 + GRACE, Gensini, LVEF, FPG, HbA1c, albumin, uric acid, eGFR, and fibrinogen. Lp(a), lipoprotein(a); MACE, major adverse cardiovascular events; CKD, Chronic kidney disease; LVEF, left ventricular ejection fraction; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; eGFR, estimated glomerular filtration rate; HR, hazard ratio; CI, confidence interval.
Back to article page